Hypertension is the major cardiovascular (CV) risk factor and remains inadequately treated in most populations. Thiazides have been the mainstay of hypertension treatment, either as monotherapy or in combination with other antihypertensives.
HYPERtENSION: DISEASE bURDEN
Hypertension is a major cardiovascular (CV) risk factor, but the real magnitude of the problem and its determinants are still not fully understood. Although there has been widespread dissemination of knowledge about hypertension, it remains inadequately treated in most populations including in India. 1 It is estimated that one of four adults in the urban population has a blood pressure (BP) reading exceeding 140/90 mm Hg. 2 Significant number of individuals with hypertension are unaware of their condition. 3 Even among persons identified as being hypertensive, only about half are being currently treated; and among patients receiving drug treatment, only half have their BP fully normalized. 4 Hypertension is often accompanied by other conditions, such as impaired glucose homeostasis (diabetes and prediabetes) and dyslipidemia often as part of metabolic syndrome.
thiazide Diuretics in Hypertension
Thiazide diuretics have been the mainstay of hypertension treatment for last five decades, either given as monotherapy or used in combination with other antihypertensive drugs. Clinical experts and guidelines are now suggesting preferential use of thiazide-like diuretics over thiazide diuretic. 6, 7 The purpose of treating hypertension is not only to decrease BP but also to decrease CV morbidity and mortality. Cardiovascular risk reduction, stroke reduction, and mortality reduction evidence are overwhelming with chlorthalidone (CTD). [8] [9] [10] National and international guidelines have recommended using thiazide-like diuretics as first-line treatment for hypertension. 11, 12 A Scientific Statement from the AHA/ACC/ASH on "Treatment of hypertension in patients with coronary artery disease" recommends CTD as a preferred diuretic in patients with stable angina, acute coronary syndrome (ACS), and heart failure (HF).
11
The National Institute for Health and Care Excellence Hypertension Clinical guideline for adults in diagnosis and management recommends that if diuretic treatment is to be initiated or changed, offer a thiazide-like diuretic, such as CTD or indapamide in preference to a conventional thiazide diuretic, such as bendroflumethiazide or hydrochlorothiazide (HCTZ). 12 The Indian Guidelines on Hypertension recommend CTD is to be preferred over HCTZ as an antihypertensive. 
201

HTNJ
Comparison with HCtZ
Chlorthalidone belongs to monosulfonamyl diuretic group, being known for long as thiazide-related diuretic. 13 Chlorthalidone is a structurally and pharmacokinetically distinct compound to HCTZ with a much longer half-life for effect and a wider volume of distribution with heavy partitioning in red blood cells. These features afford CTD a unique advantage in its capacity to act as an effective diuretic and BP lowering agent, as well as a compound that improves CV outcomes in the patient with hypertension.
14 Chlorthalidone is two times more potent than HCTZ, so 6.25 mg of CTD is equivalent to 12.5 mg of HCTZ. 15 Chlorthalidone has a longer elimination of half-life, 45 to 60 hours, than HCTZ of 8 to 15 hours. The antihypertensive action of CTD may last for 48 to 72 hours. 16 In the study conducted by Ernst et al 17 after 8 weeks, patients who were taking CTD experienced a greater reduction in BP than those taking HCTZ. The data indicated a greater reduction in 24-hour mean systolic blood pressure (SBP) with CTD compared with HCTZ (Table 1) . Late night to early morning, BP control is poor with HCTZ. Importantly, this time period has been identified as the most critical for CV events.
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Mechanism of bP Control with CtD
Hypotensive effect of CTD in hypertensive persons for a brief period is initially due to a reduction in the plasma volume. Initial action for 4 to 6 weeks is by lowering cardiac output. Later, cardiac output comes to normal, but BP remains low, which is due to reduction in peripheral vascular resistance (PVR). Sustained action is probably due to its direct action on arterioles. Chlorthalidone can reduce BP by multiple ways, such as reduction in plasma volume, reduction in PVR by interference with intracellular Ca 2+ release by noradrenaline, inhibition of rho kinase activity, reduction in arterial edema, and reduction in vascular reactivity.
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Major Global Clinical trials of CtD
The BP lowering efficacy and reduction in CV events by CTD is established in many National Institute of Health (NIH) sponsored studies, including the latest SPRINT trial. 
MUltIPlE RISk fACtOR INtERvENtION tRIAl 10
The Multiple Risk Factor Intervention Trial (MRFIT) included 12,866 high-risk men aged 35 to 57 years in 1972 at 28 institutes. They were assigned to a special intervention program that included lifestyle modifications or controlled group. At some centers, special intervention group received a diuretic (9 centers HCTZ and 6 centers CTD). The HCTZ group had a 44% higher mortality. Hence, the patients were shifted to CTD. Later with CTD the trend was reversed and the same group had a 28% lower risk.
SYStOlIC HYPERtENSION IN tHE
ElDERlY PROGRAM 9 In a multicentric, double-blind, placebo-controlled trial, 4,736 persons aged 60 years and above with SBP from 160 to 219 mm Hg and DBP < 90 mm Hg were randomized (2,365 to CTD, 12.5-25 mg/day and 2,371 to placebo). After 1 year, 83% of the CTD group and 80% of the placebo group were still taking medications. Of those still taking CTD, 88% had reached goal BP without requiring a step II drug and most had responded to 25 mg/day. The mean difference between the two groups was 17 mm Hg for SBP (p < 0.001) and 6 mm Hg for DBP (p < 0.001). The 5-year average BP was 155/72 mm Hg for the placebo group and 143/68 mm Hg for the active treatment group. The 5-year incidence of total stroke was 5.2 per 100 participants for active treatment and 8.2 per 100 for placebo. The relative In patients with isolated systolic hypertension, treatment with CTD as step 1 drug decreased the incidence of total stroke by 36%. The 5-year absolute benefit was 30 stroke events and 55 CV events per 1,000 participants.
SYStOlIC HYPERtENSION IN tHE ElDERlY PROGRAM EXtENDED 25
At the 22-year follow-up of SHEP, life expectancy gain, expressed as the area between active (n = 2,365) and placebo (n = 2,371) survival curves, was 105 days for all-cause mortality and 158 days for cardiovascular disease (CVD) death . Each month of active treatment was therefore associated with approximately 1 day extension in life expectancy. The active treatment group had higher survival free period from CV death vs the placebo group (p= 0.03), but similar survival for all-cause mortality. Thus in the SHEP trial, treatment of isolated systolic hypertension with CTD stepped-care therapy for 4.5 years was associated with longer life expectancy at 22 years of follow-up.
ANtIHYPERtENSIvE AND lIPIDlOwERING tREAtMENt tO PREvENt
HEARt AttACk tRIAl 8 The ALLHAT was a randomized, double-blind study in a total of 42,418 participants aged ≥55 years with hypertension and at least 1 other coronary heart disease (CHD) risk factor. Participants received CTD, 12.5 to 25 mg/day (n= 15,255), amlodipine, 2.5 to 10 mg/day (n= 9,048), lisinopril, 10 to 40 mg/day (n= 9054); or doxazocin (n= 9061) for 4 to 8 years. The doxazosin arm was stopped early due to a 25% higher rate of combined CVD and a two times higher rate of HF compared with the CTD arm. At 5 years, the mean BP was 133.9/75.4 mm Hg in the CTD group, 134.7/74.6 mm Hg in the amlodipine group, and 135.9/75.4 in the lisinopril group. Also at 5 years, the percentage of patients who had achieved the goal BP (< 140/90 mm Hg) was 68.2% in the CTD group, 66.3% in the amlodipine group, and 61.2% in the lisinopril group. The amlodipine group had a 38% higher risk of HF (p < 0.001) and a 35% higher risk of hospitalized/fatal HF (p < 0.001) compared to CTD. There was no significant difference observed between amlodipine and CTD groups for combined outcome of fatal CHD or nonfatal MI, allcause mortality, combined CHD, stroke, combined CVD, angina, coronary revascularization, peripheral arterial disease, cancer, or end-stage renal disease (ESRD). The lisinopril group had a 15% higher risk of stroke (p= 0.02), 10% higher risk of combined CVD (p< 0.001), 19% higher risk of HF (p< 0.001), and 11% higher risk of hospitalized or treated angina (p= 0.01). There was no significant difference observed between amlodipine and CTD groups for combined outcome of fatal CHD or nonfatal MI, all-cause mortality, combined CHD, hospitalized/fatal HF, hospitalized angina, coronary revascularization, peripheral arterial disease, cancer, or ESRD. Chlorthalidone was superior to amlodipine and lisinopril in HF prevention during the first year of follow-up, with a > 50% reduction in incidence. Beyond year 1, CTD was superior to amlodipine and equivalent to lisinopril in HF prevention. These results held true when examined by subgroups of age, race, sex, and diabetes status. Diuretics are clearly preferred over calcium channel blockers (CCBs) overall and over angiotensin converting enzyme (ACE) inhibitors, at least in the short-term, in preventing HF.
The higher potency of CTD resulted in longer duration of action that provided nighttime BP control and hence, was effective in providing additional protection from stroke and MI during early morning BP surge. 26 The most appropriate targets for SBP to reduce CV morbidity and mortality among persons without diabetes were determined in a randomized controlled trial (RCT). A total of 9,361 persons with a SBP of ≥ 130 mm Hg and an increased CV risk, but without diabetes, were randomized to a SBP target < 120 mm Hg (intensive treatment) or < 140 mm Hg (standard treatment). Use of drug classes with the strongest evidence for reduction in CV outcomes, including thiazide-type diuretics (encouraged as the firstline agent), loop diuretics (for participants with advanced chronic kidney disease), and beta-adrenergic blockers (for those with coronary artery disease) was encouraged.
SYStOlIC blOOD PRESSURE INtERvENtION tRIAl
Chlorthalidone was encouraged as the primary thiazide-type diuretic, and amlodipine as the preferred CCB. At 1 year, the mean SBP was 121.4 mm Hg in the intensive treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years, owing to a significantly lower rate of the primary composite outcome (first occurrence of a MI, ACS, stroke, HF, or CVD death) in the intensive-treatment group than in the standard-treatment group. The intensive-treatment group participants had a 25% lower relative risk of primary outcome, 38% lower relative risk of HF, 43% lower relative risk of death from CV causes, and 27% lower relative risk of death from any cause.
Diabetic Hypertension and Use of CtD
In the Systolic Hypertension in the Elderly Program (SHEP) study, a total of 4,736 men and women aged 60 years and older with SBP ≥ 160 mm Hg were included.
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Out of which, 583 had noninsulin-dependent diabetes mellitus (NIDDM) and 4,149 were nondiabetic. Rates of CVD events and of all-cause mortality were higher for diabetic than nondiabetic persons, but lower for both active treatment groups compared with the placebo groups. 9 For diabetic patients randomized to SHEP active treatment of CTD compared with diabetic patients randomized to placebo, rates were lower for major CV events, stroke, nonfatal MI plus fatal CHD, major coronary CHD events, and all-cause mortality. Results with SHEP antihypertensive treatment were similar for diabetic and nondiabetic patients and, in some cases, more favorable for diabetic patients. Since diabetic patients had higher rates than nondiabetic patients, treatment-attributable reduction in absolute risk was greater for diabetic patients. 9 Chlorthalidone treatment prevented 101 diabetic participants per 1,000 from having a CVD event, compared with 51 per 1,000 nondiabetic participants, i.e., twice as great a reduction in absolute risk. This can be seen in the graph above showing absolute risk reduction. 9 American Diabetes Association Standards of Medical Care in Diabetes 2015 recommend various drugs including a thiazide diuretic to achieve BP targets. 27 The metabolic syndrome is a clustering of clinical and biochemical characteristics related to insulin resistance. It is characterized by hypertension, central obesity, dyslipidemia (high triglycerides, low high-density lipoprotein cholesterol levels), and elevated glucose levels. To date, there is no consensus as to which class of antihypertensive medications, if any, is preferred for the treatment of hypertension in patients with the metabolic syndrome. These issues were addressed in a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The results are shown in Figure 1A and B. 28 Despite a less favorable metabolic profile, thiazidelike diuretic for hypertension offers similar, and in some instances possibly superior, CVD outcomes in older hypertensive adults with metabolic syndrome, as compared to treatment with CCBs and ACE inhibitors. At weeks 4 (p = 0.015) and 12 (p = 0.020), nighttime systolic ABP was significantly lower in the CTD group than in the HCTZ group. In contrast to the HCTZ group, the HCTZ-CR group also showed a significant (p < 0.01) reduction in 24-hour ABP. Treatment with low-dose CTD, 6.25 mg daily, significantly reduced mean 24-hour ABP as well as daytime and nighttime BP. Due to its short duration of action, no significant 24-hours ABP reduction was seen with HCTZ, 12.5 mg daily, which merely converted sustained hypertension into masked hypertension. Thus, low-dose CTD, 6.25 mg, could be used as monotherapy for treatment of essential hypertension, whereas low-dose HCTZ monotherapy was not an appropriate antihypertensive drug (Graph 1 ). In trials conducted on Indian patients, the effect on electrolyte levels with CTD was seen 15, 29, 30 (Table 2 ).
Role of Chlorthalidone 6.25 mg
Hypokalemia and Hyponatremia
Concerns about greater loss of potassium with the use of CTD has always averted clinicians from using this drug. However, this fear was possibly influenced by the Graph 1: Mean change from baseline to week-12 in average ambulatory systolic BP HTNJ historical use of higher doses of the drug (50-100 mg) than now typically used. As long as very high doses of CTD are not used, the metabolic issues particularly of hypokalemia should not be a problem (Graph 2). When low-dose CTD was used in Indian patients, the change in serum potassium levels and serum sodium was not significant (Table 3 ).
In the ALLHAT study, the change in potassium levels did not translate into more CV events or into higher allcause mortality in the CTD group compared with the other groups of lisinopril or amlodipine. 8 In the SHEP trial, during follow-up, the mean sodium concentrations was similar in the active treatment group and placebo group. 
Hyperglycemia
Pancreatic release of insulin is controlled via adenosine triphosphate-sensitive potassium channels and L-type calcium channels on the beta-cell surface. Increase in plasma glucose closes the potassium channels and increases insulin secretion. Changes in serum potassium may prevent closure of these channels leading to decrease in insulin secretion. Hypertension is often associated with insulin resistance.
In the presence of insulin resistance, decrease in beta-cell insulin release due to changes in potassium may lead to hyperglycemia in individuals with insulin resistance. 31 Thiazide-induced diabetes occurs early after initiating therapy treatment. Nondiabetic patients currently on thiazide therapy for greater than 1 year are unlikely to develop thiazide-induced diabetes. Chlorthalidoneinduced diabetes appeared to be mediated by changes in serum potassium. Each 0.5 mEq/L decrease in serum potassium from the baseline during year 1 was associated with a 45% higher risk of diabetes. Treatment with CTD doses > 12.5 mg/day is an important risk factor. 31 From the SHEP trial it was seen that fasting glucose levels increased in both groups. The incidence of diabetes was studied in CTD treated group and placebo. New cases of diabetes were 3.6% in CTD group and 2.9% in placebo at 1 year. At 3 years the incidence of diabetes was 8.6% in CTD and 7.5% in placebo. These differences are not statistically significant. Indian studies done by Pareek et al 15, 29, 30 showed the following changes in blood glucose levels (Table 4) . Thus, Indian studies have not shown cause for concern as regard to glucose levels for the duration of studies.
In a post hoc subgroup analysis in nondiabetic participants from ALLHAT who were randomized to receive treatment with CTD (n = 8,419), amlodipine (n = 4,958) or lisinopril (n = 5,034) and observed for a mean of 4.9 years. Fasting glucose levels increase in older adults with hypertension regardless of treatment type. For those taking CTD vs other medications, the risk of developing fasting blood glucose levels higher than 125 mg/dL is modestly greater, but there is no conclusive or consistent evidence that this diuretic-associated increase in diabetes mellitus risk increases the risk of clinical events.
32
Cv bENEfItS Of CtD IN PAtIENtS wItH PREEXIStING AND NEw-ONSEt DIAbEtES
The SHEP collaborative research group studied the longterm effects of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. 33 At a mean follow-up of 14.3 years, CV mortality rate was significantly lower in the CTD group (19%) than in the placebo group (22%). Diabetes that developed during trial in placebo treated patients (n= 169) was associated with increased CV adverse outcome and total mortality rate. However, diabetes that developed among patients during diuretic therapy did not have significant associations with CV mortality rate or total mortality rate. Diuretic treatment in subjects who had diabetes was strongly associated with lower long-term CV mortality rate and total mortality rate.
The CTD based treatment improved long-term outcomes, especially among subjects who had diabetes. Subjects who had diabetes associated with chlorthalidone had no significant increase in CV events and had a better prognosis than did those who had preexisting diabetes.
In the ALLHAT diabetes extension study, 34 participants on CTD with incident diabetes vs no diabetes had consistently lower, non significant risk for CVD mortality, all cause mortality and non CVD mortality than participants on amlodipine or lisinopril with incident diabetes. Participants with incident diabetes had elevated CHD risk compared with those with no diabetes, but those on CTD had significantly lower risk than those on lisinopril. In conclusion, the findings suggest that thiazide-associated incident DM is associated with lower CVD mortality and incident DM over an average of 6.9 years. Therefore, concerns regarding potentially adverse diabetic effects associated with thiazide-type diuretic therapy should not inhibit its use. In this regard, a recent pooled analysis of 5 statin studies 35 showed that incident DM was more common in persons treated with intensive-dose therapy versus moderate-dose therapy. Nonetheless, the benefits of reduced cholesterol were deemed to outweigh any possible deleterious effects of incident diabetes mellitus on CVD outcomes. Similarly, thiazide-like diuretics have been shown to be highly effective for preventing CVD outcomes through decades of rigorously controlled clinical trials.
tHIAZIDE-lIkE DIUREtICS AND REDUCED RISk Of HIP AND PElvIC fRACtURES IN OlDER ADUltS
The ALLHAT collaborative research group studied the association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults. 36 A total of 22,180 participants were followed-up for 8 years. After trial completion, 16,622 participants were followed for additional 5 years. Participants randomized to receive CTD vs amlodipine or lisinopril had a lower risk of fracture on adjusted analysis (p= 0.04). Risk of fracture was significantly lower in participants randomized to receive CTD vs lisinopril (p = 0.04). These findings from a large randomized clinical trial provide evidence of a beneficial effect of thiazide-type diuretic therapy in reducing hip and pelvic fracture risk compared with treatment with other antihypertensive medications.
CONClUSION
Clinical experts, national, and international guidelines are suggesting preferential use of thiazide like diuretic over thiazide diuretic. Chlorthalidone is a structurally and pharmacokinetically distinct compound to HCTZ with two times more potency and much longer half-life. It ensures effective systolic and diastolic BP reduction in daytime, nighttime, 24-hour ambulatory BP recordings. The renaissance of CTD is due to various global large trials like TOMHS, MRFIT, SHEP, ALLHAT, and SPRINT showing CV events reduction, stroke reduction, and most importantly, mortality reduction across various patient subgroups.
The dose of CTD 6.25 mg is most suitable for Indian patients. Published Indian evidence indicates that this low dose of CTD could reduce dose-related concerns about metabolic adverse effects and may lead to its wider usage as an antihypertensive agent.
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